

# Contents

<b>Abbreviations and acronyms</b>	v
<b>List of participants</b>	vii
<b>Declarations of interests of the Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD), observers, reviewers and consultants</b>	xi
<b>Acknowledgements</b>	xii
<b>Executive summary</b>	xiii
<b>1. Introduction</b>	1
<b>2. Open session</b>	2
<b>3. General items</b>	7
3.1 Methods used to establish the second EDL	7
3.1.1 Changes to entries in the first EDL	8
3.1.2 Submissions for new product categories	8
3.1.3 Proposals for general and anatomical pathology tests	10
3.1.4 Proposal for inclusion of therapeutic drug monitoring tests	10
3.1.5 Public consultation	11
3.1.6 Process for decision-making	11
3.2 Changes to the structure of the List	11
3.3 Country implementation plans	12
3.4 Integration of the List within other WHO initiatives	13
3.4.1 Integration with the Essential Medicines List	13
3.4.2 Integration with the WHO Expert Committee on Biological Standardization	14
3.5 Eligibility for prequalification	14
<b>4. Summary of recommendations</b>	16
4.1 General recommendations	16
4.2 Additions to the List	20
4.3 Deletions from the List	25
4.4 Changes to listings	25
4.5 Rejected proposed changes	25
4.6 Rejected applications	28
<b>5. Accepted applications for the second Model List of Essential In Vitro Diagnostics</b>	29
Section I.b. Disease-specific tests for use in community settings and health facilities without laboratories	29
<i>Leishmania</i> rk39 antigen: rapid diagnostic test	29
<i>Vibrio cholerae</i> antigen: rapid diagnostic test	33
Section II.a General in vitro diagnostics for clinical laboratories	38
Clinical chemistry	38
Procalcitonin in serum and plasma: immunoassay	38
Section II.b Disease-specific in vitro diagnostics for clinical laboratories	43
Cancer	43
Alpha fetoprotein immunoassay for diagnosis of liver and germ-cell tumours	43

Basic panel of immunohistochemical tests for diagnosis of lymphoma	48
Basic panel of immunohistochemical tests for diagnosis of solid tumours	53
<i>BCR-ABL1</i> and <i>ABL1</i> transcripts for diagnosis of chronic myelogenous leukaemia (CML) and CML variants and prognosis of acute lymphoblastic leukaemia (ALL)	57
Essential panel of antibodies for flow cytometry for leukaemia	62
Faecal immunochemical test (FIT) for screening for colorectal cancer	66
Guaiac faecal occult blood test	71
Human chorionic gonadotrophin plus $\beta$ -human chorionic gonadotrophin immunoassay to aid in the diagnosis of and surveillance for germ-cell tumours and gestational trophoblastic disease	76
Human epidermal growth factor receptor 2 (HER2) or tyrosine-protein kinase receptor (erbB-2) or overexpression: immunohistochemical tests to aid in diagnosis, prognosis and treatment of breast cancer	80
Lactate dehydrogenase activity to aid in the prognosis and monitoring of haematological malignancies and germ-cell tumours	84
Oestrogen and progesterone receptors in breast cancer: immunohistochemical test	88
Papanicolaou smear test	92
Prostate-specific antigen	96
HIV infection	100
Histoplasma antigen enzyme immunoassay	100
Influenza	104
Influenza antigen: rapid immunoassay to aid in diagnosis of seasonal influenza	104
Influenza A and B: nucleic acid test for diagnosis of seasonal influenza	108
Neglected tropical diseases	112
Dengue virus antibody enzyme immunoassay or rapid diagnostic test	112
Dengue virus antigen (NS1) enzyme immunoassay or rapid diagnostic test	116
Dengue virus nucleic acid test	120
Kato-Katz test for soil-transmitted helminths and intestinal schistosomes	125
Primary immunodeficiency disorders	128
Lymphocyte subtypes (CD4, CD8, CD20 and CD16/56 cells, B cells and NK cells)	128
Plasma levels of immunoglobulins G, A and M	133
Plasma and urine protein electrophoresis and immunofixation	138
Response to tetanus and pneumococcus vaccines	143
Sexually transmitted infections	147
<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> genomic DNA	147
<i>Treponema pallidum</i> antibodies: rapid diagnostic test for diagnosis or as an aid in diagnosis of syphilis	151
Zika virus infection	154
Zika virus: enzyme-linked immunoassay for immunoglobulin M	154
Test for Zika virus nucleic acid	158

## Annex 1

Second Model List of Essential In Vitro Diagnostics (EDL)	163
---	-----

## Index

	215
--	-----